-
公开(公告)号：US20240277758A1
公开(公告)日：2024-08-22
申请号：US18397569
申请日：2023-12-27
发明人： Craig Sherman , Micah Bodner , Jon Marshall
IPC分类号： A61K33/04 , A61K9/00 , A61K31/717
CPC分类号： A61K33/04 , A61K9/0014 , A61K31/717
摘要： Provided herein are formulations comprising sodium thiosulfate. Also provided herein are methods of treating, preventing or ameliorating a sulfur mustard skin injury in a subject, wherein the methods comprise contacting the subject with a formulation provided herein.
-
公开(公告)号：US20240165046A1
公开(公告)日：2024-05-23
申请号：US18282545
申请日：2022-01-28
发明人： Jani Kuula , Eija Raussi-Lehto , Orlando Rojas , Rubina Ajdary , Tomi Mikkola
IPC分类号： A61K9/70 , A61K9/00 , A61K31/717 , A61L27/20 , A61L27/54
CPC分类号： A61K9/70 , A61K9/0024 , A61K31/717 , A61L27/20 , A61L27/54 , A61L2300/412 , A61L2300/64 , A61L2400/06 , A61L2400/12 , A61L2430/22 , A61L2430/34
摘要： According to an example aspect of the present invention, there is provided a composition for use in the treatment of urinary or faecal incontinence, the composition comprising a nanostructured cellulosic material.
-
公开(公告)号：US11944703B2
公开(公告)日：2024-04-02
申请号：US18365024
申请日：2023-08-03
IPC分类号： A61F9/007 , A61F9/00 , A61K9/00 , A61K9/16 , A61K31/717 , A61K31/718 , A61K31/722 , A61K31/728 , A61K31/737 , A61K47/36 , A61M5/31 , A61M5/48 , A61K9/14
CPC分类号： A61K9/0048 , A61F9/0017 , A61F9/0026 , A61F9/007 , A61F9/00736 , A61K9/0051 , A61K9/1635 , A61K31/717 , A61K31/718 , A61K31/722 , A61K31/728 , A61K31/737 , A61K47/36 , A61M5/486 , A61K9/14 , A61M2005/3103 , A61M2210/0612
摘要： An ocular medical injector is provided for drug delivery. A method includes inserting a puncture member of the medical injector into the eye until the puncture member reaches the suprachoroidal space (SCS). The puncture member defines a lumen therethrough. With the puncture member disposed within the SCS, a flexible cannula is advanced distally through the lumen of the puncture member, beyond the distal end portion of the puncture member and along the SCS towards a posterior region of the eye. The flexible cannula has an atraumatic distal tip and defines a lumen therethrough. With the distal tip of the flexible cannula disposed within the SCS beyond a distal end portion of the puncture member, a therapeutic substance is administered to the SCS.
-
公开(公告)号：US11752101B2
公开(公告)日：2023-09-12
申请号：US17711495
申请日：2022-04-01
IPC分类号： A61F9/007 , A61F9/00 , A61M5/31 , A61K9/00 , A61K9/16 , A61K31/717 , A61K31/718 , A61K31/722 , A61K31/728 , A61K31/737 , A61K47/36 , A61M5/48 , A61K9/14
CPC分类号： A61K9/0048 , A61F9/007 , A61F9/0017 , A61F9/0026 , A61F9/00736 , A61K9/0051 , A61K9/1635 , A61K31/717 , A61K31/718 , A61K31/722 , A61K31/728 , A61K31/737 , A61K47/36 , A61M5/486 , A61K9/14 , A61M2005/3103 , A61M2210/0612
摘要： An ocular medical injector is provided for drug delivery. A method includes inserting a puncture member of the medical injector into the eye until the puncture member reaches the SCS. The puncture member defines a lumen therethrough. With the puncture member disposed within the SCS, a flexible cannula is advanced distally through the lumen of the puncture member, beyond the distal end portion of the puncture member and along the SCS towards a posterior region of the eye. The flexible cannula has an atraumatic distal tip and defines a lumen therethrough. With the distal tip of the flexible cannula disposed within the SCS beyond a distal end portion of the puncture member, a therapeutic substance is administered to the SCS.
-
公开(公告)号：US20230270799A1
公开(公告)日：2023-08-31
申请号：US18004082
申请日：2021-07-01
发明人： José Manuel DOMÍNGUEZ VERA , José Manuel DELGADO LÓPEZ , Ana GONZÁLEZ GARNICA , Gloria Belén RAMIREZ RODRIGUEZ , Natividad GÁLVEZ RODRÍGUEZ , Laura SABIO RODRÍGUEZ
IPC分类号： A61K35/747 , A61P31/04 , A61K35/745 , A01N63/20 , A01N43/16 , A61K31/717 , C12N1/20 , A23P20/10 , A23L33/135 , C12N11/04
CPC分类号： A61K35/747 , A61P31/04 , A61K35/745 , A01N63/20 , A01N43/16 , A61K31/717 , C12N1/20 , A23P20/105 , A23L33/135 , C12N11/04 , A23Y2220/35 , A23Y2220/37
摘要： The invention relates to biomaterials, which comprise a bacterial cellulose matrix and probiotics entrapped in said bacterial cellulose. The invention also relates to methods for obtaining the biomaterial, as well as uses of the biomaterial in medicine. It also relates to coated food products wherein the coat is composed of said biomaterial wherein the coat acts to prevent the proliferation of undesired bacteria. It also relates to packaged medical devices, wherein the package comprises said biomaterial also preventing growth of pathogenic bacteria.
-
公开(公告)号：US20230263818A1
公开(公告)日：2023-08-24
申请号：US18309440
申请日：2023-04-28
发明人： Aram Oganesian , Nipun Davar , Jim Hwaicher Kou
IPC分类号： A61K31/706 , A61K9/00 , A61K9/20 , A61K9/48 , A61K31/20 , A61K31/7016 , A61K31/717
CPC分类号： A61K31/706 , A61K9/0056 , A61K9/20 , A61K9/4891 , A61K31/20 , A61K31/7016 , A61K31/717
摘要： Embodiments of the present invention provide solid oral dosage forms that upon daily administration to a subject provide plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily IV dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided according to embodiments of the present invention are solid oral dosage forms wherein upon daily administration to a subject provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided are methods of treatment using a solid oral dosage form according to an embodiment of the invention.
-
7.发明公开公开(公告)号：US20230174679A1
公开(公告)日：2023-06-08
申请号：US17806323
申请日：2022-06-10
发明人： MARK H. SCHOENFISCH , MONA JASMINE R. AHONEN , LEI YANG , HAIBAO JIN , EVAN SCOTT FEURA , SARA ELIZABETH MALONEY
IPC分类号： C08B15/04 , C08B37/08 , C08B37/00 , A61K9/06 , A61K31/717 , A61K31/726 , A61L27/34 , A61K31/728
CPC分类号： C08B15/04 , C08B37/0072 , C08B37/0063 , A61K9/06 , A61K31/717 , A61K31/726 , A61L27/34 , A61K31/728 , A61L2300/404
摘要： Several embodiments of NO releasing structures are disclosed. In some embodiments, the structures are covalently modified to store and release nitric oxide. Some embodiments pertain to methods of making and use of these structures. The covalently modified polymer structures may be tailored to release nitric oxide in a controlled manner and are useful for treatment of various medical conditions.
-
8.发明申请公开(公告)号：US20180185406A1
公开(公告)日：2018-07-05
申请号：US15908274
申请日：2018-02-28
申请人： Joshua D. Levine , Robert A. Levine
发明人： Joshua D. Levine , Robert A. Levine
IPC分类号： A61K31/717 , A61K47/38 , A61K9/00 , A61K9/12
CPC分类号： A61K31/717 , A61K9/0043 , A61K9/12 , A61K47/38
摘要： A composition for use in a nasal application, the composition including an aqueous carrier and a viscosity agent. The viscosity agent is in the range of about 4% to about 15% by weight. The viscosity agent is in solution with the aqueous carrier. The solution of the aqueous carrier and the viscosity agent is configured as a thixotropic composition.
-
公开(公告)号：US09962374B2
公开(公告)日：2018-05-08
申请号：US15177760
申请日：2016-06-09
IPC分类号： A61K9/22 , A61K31/715 , A61K31/435 , A61K31/4418 , A61K9/20 , A61K31/4412 , A61K9/00 , A61K31/717 , A61K31/44
CPC分类号： A61K31/4418 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2095 , A61K31/44 , A61K31/4412 , A61K31/717
摘要： The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and/or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis.
-
公开(公告)号：US09826768B2
公开(公告)日：2017-11-28
申请号：US14771891
申请日：2014-04-08
发明人： Puspendu Deo , Kathryn Brown , David E. Wallick , Robert L. Sammler , Yongfu Li
IPC分类号： A61K31/717 , C08L1/28 , C08J3/03 , A23L1/308 , C08J3/075 , A23L29/262 , A23L33/24
CPC分类号： A23L29/262 , A23L33/24 , A23V2002/00 , A61K31/717 , C08J3/03 , C08J3/075 , C08J2301/28 , C08L1/28
摘要： A process for preparing an aqueous solution of a methylcellulose having anhydroglucose units joined by 1-4 linkages wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is 0.36 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups, comprises the step of mixing the methylcellulose with an aqueous liquid at a temperature of not higher than 10° C. at a shear rate of at least 1000 s−1.
-
-
-
-
-
-
-
-
-
搜索结果
676 条记录 (耗时 0.04 秒)
